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Strengths and limitations of this study
 ► For the first time, this systematic review brings to-
gether contemporary evidence on aspects of periop-
erative care for people with total knee replacement 
and their effects on long-term pain.
 ► Only studies assessed to be at low risk of bias were 
included in the narrative synthesis.
 ► Intervention and outcome heterogeneity precluded 
meta-analysis.
AbStrACt
Objectives For many people with advanced osteoarthritis, 
total knee replacement (TKR) is an effective treatment 
for relieving pain and improving function. Features of 
perioperative care may be associated with the adverse 
event of chronic pain 6 months or longer after surgery; 
effects may be direct, for example, through nerve damage 
or surgical complications, or indirect through adverse 
events. This systematic review aims to evaluate whether 
non-surgical perioperative interventions prevent long-term 
pain after TKR.
Methods We conducted a systematic review of 
perioperative interventions for adults with osteoarthritis 
receiving primary TKR evaluated in a randomised 
controlled trial (RCT). We searched The Cochrane Library, 
MEDLINE, Embase, PsycINFO and CINAHL until February 
2018. After screening, two reviewers evaluated articles. 
Studies at low risk of bias according to the Cochrane tool 
were included.
Interventions Perioperative non-surgical interventions; 
control receiving no intervention or alternative 
treatment.
Primary and secondary outcome measures Pain or 
score with pain component assessed at 6 months or longer 
postoperative.
results 44 RCTs at low risk of bias assessed long-term 
pain. Intervention heterogeneity precluded meta-analysis 
and definitive statements on effectiveness. Good-
quality research provided generally weak evidence for 
small reductions in long-term pain with local infiltration 
analgesia (three studies), ketamine infusion (one study), 
pregabalin (one study) and supported early discharge (one 
study) compared with no intervention. For electric muscle 
stimulation (two studies), anabolic steroids (one study) 
and walking training (one study) there was a suggestion 
of more clinically important benefit. No concerns relating 
to long-term adverse events were reported. For a range 
of treatments there was no evidence linking them with 
unfavourable pain outcomes.
Conclusions To prevent chronic pain after TKR, several 
perioperative interventions show benefits and merit 
further research. Good-quality studies assessing long-
term pain after perioperative interventions are feasible 
and necessary to ensure that patients with osteoarthritis 
achieve good long-term outcomes after TKR.
bACkgrOund
In the USA about 13% of men and 19% of 
women will be diagnosed with knee osteo-
arthritis and over half will receive a total 
knee replacement (TKR).1 For people with 
advanced osteoarthritis unresponsive to 
pharmacological or conservative treatments, 
TKR aims to relieve pain and improve func-
tion. In the UK, nearly 100 000 primary TKRs 
were performed in 20172 3 and in the USA in 
2010, an estimated 4.7 million people were 
living with a TKR.4 Despite good outcomes 
for many, some people report long-term pain 
and are disappointed with their surgery.5 6 
After TKR, pain levels plateau from about 6 
months7 8 after which persistent pain is consid-
ered ‘chronic’9 and is reported by 10%–34% 
of patients.10
The mechanisms that influence the devel-
opment of chronic pain after TKR may be 
biological, mechanical and psychosocial. 
Biological explanations include the sensi-
tising impact of long-term pain from osteo-
arthritis,11 12 inflammation, infection and 
localised nerve injury.13 Mechanical expla-
nations include altered gait, prosthesis 
loosening and effects on ligaments.14 15 
Psychological factors including depression 
and catastrophising may also influence 
outcomes.16–19 Much research has focused 
on preoperative predictors of outcomes and 
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these include pain intensity, presence of widespread pain, 
anxiety, depression and catastrophising.10 20 However, 
attempts to target or modify preoperative care have, as 
yet, shown no benefit regarding chronic pain or other 
long-term patient outcomes.10 21–23
Perioperative risk factors suggest that appropriate inter-
ventions may reduce long-term pain. For example, acute 
postoperative pain, which may be a direct consequence 
of the operation, anaesthetic protocol and subsequent 
analgesia, or related to particular aspects of care, is an 
acknowledged risk factor for chronic postsurgical pain.24
In the perioperative period from hospital admission to 
the early stages of recovery, care focuses on acute pain 
management, prevention of adverse events, facilitation 
of early mobilisation and timely discharge. However, 
for people with osteoarthritis the key aim of TKR is the 
achievement of a long-term painless and well-functioning 
knee with no adverse events. All aspects of perioperative 
care should work together to achieve this.
Any treatment in the perioperative period including 
pain management, blood conservation, deep vein throm-
bosis (DVT) and infection prevention, and inpatient reha-
bilitation could potentially affect patient recovery and 
chronic pain, either directly or indirectly. Direct mech-
anisms may be through prevention of nerve damage,25 
post-thrombotic syndrome,26 reperfusion injury27 and 
articular bleeding.28 For other treatments, pathways 
leading to long-term pain may be indirect, possibly being 
mediated through increased risks of adverse events.29 
Irrespective of mechanism, chronic pain is a highly prev-
alent adverse event after TKR and should be considered 
along with infection, DVT and other complications in the 
safety profile of interventions.
Our systematic review of randomised controlled trials 
(RCT) aims to evaluate the effectiveness of treatments 
in the perioperative period in preventing long-term pain 
after TKR. By focusing on studies with low risk of bias we 
aim to identify interventions with robust evidence of long-
term effectiveness and identify gaps in the research base.
MethOdS
The systematic review protocol was registered (PROS-
PERO CRD42017041382) and PRISMA reporting 
guidelines used.30 A checklist is included as online supple-
mentary material.
Patient and public involvement
As part of the STAR programme of research (NIHR 
RP-PG-0613-20001), this review benefited from exten-
sive patient and public involvement. Advice was sought 
from patients and stakeholders at a group discussion in 
March 2016 with decisions made on inclusion criteria 
and outcomes. Our patient advisory group comprises five 
patients with experience of long-term pain after TKR, 
supported by a dedicated coordinator. This group will 
advise on dissemination of the study results to a general 
audience including plain language summaries.
eligibility criteria
Studies were eligible if they satisfied Population-Inter-
vention-Comparator-Outcome Study criteria defined in 
the protocol. Participants were adults receiving unilat-
eral primary TKR with osteoarthritis in at least 75% of 
patients. Pharmacological or non-pharmacological 
interventions commenced in the perioperative setting 
with ‘peri-operative’ reflecting the time from hospital 
admission to immediately postdischarge. Interventions 
relating to implant designs and surgical procedures were 
excluded. The comparator was usual care, placebo or an 
alternative intervention. Outcomes were, in preference, 
patient-reported joint-specific pain intensity measured by 
tools such as the Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) or Oxford Knee 
Score (OKS). If joint-specific measures were unavailable, 
pain dimensions from quality of life measures were used 
or pain rated on a visual analogue scale (VAS) or numer-
ical rating scale (NRS). We also considered composite 
patient-reported outcome measures and surgeon scores 
which included a pain intensity component, such as 
the American Knee Society Score (KSS) and Hospital 
for Special Surgery (HSS) score. Measures specifically 
of neuropathic pain were also used. The occurrence of 
adverse events was summarised. The studies included 
were RCTs with follow-up at ≥6 months after surgery and a 
pain outcome or score including pain. Authors of studies 
were contacted regarding incomplete pain outcome data.
database searches
We established an Endnote database of all RCTs in TKR. 
On 14 February 2018, a search from database incep-
tion was conducted in: The Cochrane Library; MEDLINE, 
Embase and PsycINFO on Ovid; and CINAHL on EBSCO-
host. The MEDLINE search strategy is included as online 
supplementary material. Citations of key articles were 
tracked in Web of Science. No language restrictions 
were applied, and translations made. Studies reported 
as abstracts or unobtainable using interlibrary loans and 
author contact were excluded.
Screening and data extraction
We imported records into Endnote X7 (Thomson 
Reuters). An initial screen by one reviewer excluded 
clearly irrelevant articles. Subsequently, abstracts and full 
articles were screened independently by two reviewers 
and reasons for exclusion recorded.
Data were extracted onto piloted forms and an Excel 
spreadsheet by one reviewer, specifically: country; dates; 
participants (indication, age, sex); inclusion and exclu-
sion criteria; intervention and control content; setting, 
timing, duration and intensity of intervention; follow-up 
intervals; losses to follow-up; pain outcome data; and 
serious adverse events. Data were checked against source 
material by a second reviewer.
Authors were contacted for missing data, and data 
provided for previous reviews were used.10 31
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Quality assessment
Potential sources of bias were assessed by two experi-
enced reviewers using the Cochrane risk of bias tool,32 
specifically: the randomisation process; deviations from 
intended interventions; missing outcome data (>20%), 
measurement of the outcome; and selection of the 
reported result. Studies with serious concerns relating 
to risk of bias were considered high risk and those with 
limited reporting unclear risk. Studies with high or 
unclear risk of bias were excluded from the narrative 
synthesis but are included in online supplementary 
summary tables with reasons for exclusion.
data analysis
Insufficient studies with similar interventions and 
outcomes were identified for meta-analysis, and a narra-
tive synthesis is presented. Results reported with p values 
≤0.001 were considered ‘strong’ evidence of effective-
ness,33 p values 0.001–0.05 ‘some’ evidence and p values 
0.05–0.1 ‘weak’ evidence. When authors reported results 
‘statistically significant’ with no p value, this was noted. 
Where possible, effect sizes were compared with published 
minimal clinically important differences (MCID). 
Concerns relating to adverse events were summarised.
reSultS
Figure 1 shows review progress and reasons for exclusion. 
Of 1515 RCTs of interventions in the perioperative setting, 
1385 had no long-term follow-up. Perioperative interven-
tions with follow-up of ≥6 months were evaluated in 130 
RCTs of which 76 reported a pain outcome or score with a 
pain component. Detailed intervention and study charac-
teristics and risk of bias assessments are provided as online 
supplementary material. Studies excluded had concerns 
for risk of bias pertaining to at least one of: large baseline 
differences in group characteristics or numbers in groups 
(n=4); incomplete outcome data (n=15); limited or selec-
tive reporting (n=12); or unblinded surgeon follow-up 
(n=1).
Details of 44 studies assessed to be at low risk of bias 
are summarised in table 1. In 34 studies, patients received 
TKR exclusively for osteoarthritis and in three studies, 
75% or more patients had osteoarthritis. In seven studies 
there was no information on reason for surgery but 
there was no suggestion that patients had an indication 
other than osteoarthritis. Interventions focused on pain 
management (n=20), tourniquets (n=5), compression 
bandages (n=1), blood conservation (n=7), denosumab 
(n=1), continuous passive motion (CPM, n=2), electrical 
stimulation (n=2), rehabilitation (n=4), wound manage-
ment (n=1) and anabolic steroids (n=1). Primary pain 
outcome measures reported were VAS or NRS pain 
(n=12), WOMAC pain (n=7), Knee injury and Osteoar-
thritis Outcome Score (KOOS) pain (n=3), Leeds Assess-
ment of Neuropathic Symptoms and Signs Pain Scale 
(S-LANSS) (n=1), Short Form 36 (SF-36) bodily pain 
(n=1), or composite scores including a pain measure, 
OKS or WOMAC (n=10), KSS or HSS (n=10). Latest 
outcomes were recorded at 6 months (n=12), 12 months 
(n=26) and 24 months (n=6). Reporting of adverse events 
covered the entire follow-up period in 27 studies, short 
term after surgery in 15 studies, but were not reported in 
two studies.
Pain management
We identified 20 RCTs with 2393 participants evaluating 
components of multimodal pain management. Four 
studies each were from China and the USA, two each from 
Canada and the UK and one each from Australia, Finland, 
France, Iran, Singapore, South Korea, Sweden and The 
Netherlands. All were conducted at a single centre and, in 
those with dates, participants were recruited between 2004 
and 2015. Sample sizes ranged from 44 to 280 participants, 
with a median of 96. Four studies had three trial arms and 
16 had two. The range of mean or median ages of partici-
pants in randomised groups was 61–73 years and, in 17/19 
studies with data, a majority of participants were women.
Femoral nerve block
Femoral nerve blocks (FNB) were studied in 10 RCTs.
Three RCTs compared FNB with no FNB. In one 
study with 55 patients, WOMAC pain scores at 1 year 
were similar in patients receiving single-shot FNB and 
untreated controls.34 All patients received local infiltra-
tion analgesia (LIA) and patient-controlled analgesia 
(PCA). In another study with all participants receiving 
LIA, 150 were randomised to receive single-shot FNB 
with or without sciatic nerve block (SNB), or general 
anaesthesia.35 There were no differences in HSS scores 
between groups at 6 months. Continuous FNB was 
compared with oral hydrocodone opioid in 62 patients 
receiving PCA.36 There was some evidence for ‘pain using 
stairs’ favouring hydrocodone (p=0.01) but no differ-
ence in overall NRS-rated pain at 1 year and concern over 
venous thromboembolism in 4/31 participants treated 
with hydrocodone.
In two RCTs, continuous FNB was compared with PCA. 
In one study with 60 participants, the KSS at 6 months was 
similar between groups.37 In another study with 280 partic-
ipants, there was some evidence for higher incidence of 
NRS-rated pain at 6 months in the PCA group than the 
FNB group (p=0.021) but not at 12 months (p=0.273).38
Two RCTs compared FNB with LIA. In one study, all 
157 participants also received PCA.39 At 1 year, KSS values 
were similar in single-shot FNB and LIA groups. In the 
other study, 94 participants were randomised to receive 
single-shot FNB with continuous epidural infusion or LIA 
through an intra-articular catheter.40 VAS-rated pain was 
similar between groups at 1 year.
In two RCTs, FNB procedures were compared. In one 
study with 99 patients randomised to two FNB concentra-
tions, there was no difference in WOMAC score between 
groups at 12 months.41 In another study with 61 partici-
pants allocated to two different durations of FNB, there 
was no difference in WOMAC pain scores at 1 year.42 In 
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Figure 1 Systematic review flow diagram.
these studies, all participants received either SNB41 or 
PCA.42
Single-shot FNB was compared with single adductor 
canal block in one RCT with 98 participants, all receiving 
LIA.43 At 6 months there was no difference in VAS-rated 
pain.
Sciatic nerve block
In one study, 89 patients were randomised to single-shot 
SNB, continuous SNB, or PCA.44 All patients received 
FNB. At 12 months, there were no differences in pain 
for single-shot SNB and continuous SNB on the WOMAC 
pain scale or VAS-rated pain at rest or during mobilisation. 
Protected by copyright.
 o
n
 Septem
ber 19, 2019 at University of Bristol Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028093 on 6 September 2019. Downloaded from 
5Beswick AD, et al. BMJ Open 2019;9:e028093. doi:10.1136/bmjopen-2018-028093
Open access
Table 1 Perioperative interventions with follow-up for pain or score at 6 months or later and assessed to be at low risk of bias
Study, country, patient 
recruitment dates
Setting
Treatment common to 
randomised groups Intervention Patients, n
Follow-up
Group difference
Pain management: nerve blocks
Albrecht et al41
Canada, 2009–2011
1 hospital
SNB 1. FNB continuous high
2. FNB continuous low
3. FNB single
99 1 year
WOMAC score: no difference
(p=0.68)
Choy et al42
Korea, 2006–2007
1 surgeon
PCA 1. FNB continuous long
2. FNB continuous short
61 1 year
WOMAC pain: no difference (p=0.2)
Fan et al39
China, 2012–2014
2 surgeons
PCA 1. FNB single
2. LIA
157 1 year
KSS: no difference (p=0.51)
Gao et al35
China, 2014–2015
1 centre
LIA 1. General anaesthesia
2. FNB single
3. FNB/SNB single
150 6 months
HSS score: no significant difference 
(p>0.05)
Macrinici et al43
USA, before 2017
1 centre
LIA 1. ACB single
2. FNB single
98 6 months
VAS pain: no difference
Nader et al36
USA, 2007–2008
1 surgeon
PCA 1. FNB continuous
2. Oral opioid
62 1 year
NRS pain stair: some evidence 
favouring opioid (p=0.01) but not 
consistent. Overall NRS pain: no 
difference (p=1.0)
VTE: concern opioid
Peng et al38
China, Before 2014
1 centre
  1. FNB continuous
2. PCA
280 6 months and 1 year
NRS pain: some evidence favouring 
FNB at 6 months (p=0.021); no 
difference at 1 year (p=0.273)
Reinhardt et al40
USA, 2010–2012
2 surgeons
  1. FNB single/ epidural
2. LIA 48 hours
94 1 year
VAS pain: no difference
Wegener et al44
The Netherlands, 2008–
2010
1 centre
FNB 1. SNB single
2. SNB continuous
3. PCA
89 1 year
WOMAC pain: no difference (p=0.81)
Widmer et al34
Australia, before 2012
2 surgeons
LIA, PCA 1.  FNB single
2.  Control no FNB
55 1 year
WOMAC pain: no difference (p=0.74)
Wu and Wong37
China, 2009–2011
1 centre
  1. FNB continuous
2. PCA
60 6 months
KSS: no difference (p=0.513)
Pain management: LIA
McDonald et al52
UK, 2010–2011
1 hospital
  1. LIA
2. PCA
222 1 year
OKS: no difference (p=0.915)
Motififard et al49
Iran, 2014–2015
1 hospital
  1. LIA pre-emptive 
injection
2. Control saline with 
epinephrine
120 6 months
KSS: weak evidence favouring LIA 
(p=0.07). Difference between groups 
(14.2/200) less than MCID (12.3/200)
Niemeläinen et al47
Finland, 2011–2012
1 hospital
PCA 1. LIA
2. Control saline
56 1 year
OKS: weak evidence from means 
and CIs favouring LIA. Difference 
(2.7/48) less than MCID (4.0/48)
Sean et al53
Singapore, 2004–2005
1 hospital
PCA 1. LIA with corticosteroid
2. LIA no corticosteroid
100 6 months and 2 years
OKS: no difference
Continued
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Study, country, patient 
recruitment dates
Setting
Treatment common to 
randomised groups Intervention Patients, n
Follow-up
Group difference
Williams et al51
Canada, Before 2013
2 surgeons
LIA, PCA 1. LIA 48 hours
2. Control saline
51 6 months and 1 year
VAS pain: no difference (6 months 
p=0.836, 1 year p=0.767)
Wylde et al45
UK, 2009–2012
1 centre
FNB, PCA 1. LIA
2. Control no LIA
280 6 months and 1 year
WOMAC pain: weak evidence 
favouring LIA at 6 months p=0.063; 
1 year p=0.107. Mean difference at 
1 year (3.8/100) lower than MCID 
(8–9/100)
Pain management: celecoxib
Meunier et al54
Sweden, 2004–2005
1 centre
PCA 1. Celecoxib
2. Control placebo
44 1 year
KOOS/VAS pain: no difference
Pain management: ketamine/nefopam
Aveline et al55
France, 2005
1 centre
PCA 1. Ketamine infusion
2. Nefopam infusion
3. Control saline
75 6 months and 1 year
DN4/VAS pain: some evidence 
favouring ketamine (for DN4 p=0.02). 
Few patients had neuropathic pain 
at 12 months.
Pain management: pregabalin
Buvanendran et al56
USA, 2006–2007
Single centre
LIA, PCA 1. Pregabalin
2. Control placebo
240 6 months
NRS pain: some evidence favouring 
pregabalin at 6 months  
(p=0.0176)
S-LANSS pain: no neuropathic 
pain reported in pregabalin group 
compared with 5.2% of patients in 
control group (p=0.014)
Sedation and confusion day  
0 and day 1: concern  
pregabalin
Tourniquet
Ejaz et al58
Denmark, 2011–2012
1 centre
Tranexamic acid 1. Tourniquet
2. Tourniquet not inflated
64 6 months and 1 year
KOOS pain: no significant difference
Huang et al60
China, 2015
1 centre
Tranexamic acid 1. Tourniquet
2. No tourniquet
100 6 months
VAS pain: no difference
(p=0.728)
Wound: concern tourniquet
Liu et al59
Australia, Before 2014
1 surgeon
  1. Tourniquet
2. Tourniquet not inflated
20 6 months and 1 year
OKS: no significant difference
Transfusion: concern
tourniquet
Mittal et al61
Australia, 2008–2010
1 centre
  1. Tourniquet short 
duration
2. Tourniquet long 
duration
65 1 year
OKS: weak evidence from means 
and CIs on graph favouring long 
duration at 1 year. Mean difference 
(5) greater than MCID (4)
Transfusions/adverse events: 
concern short
Table 1 Continued
Continued
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Study, country, patient 
recruitment dates
Setting
Treatment common to 
randomised groups Intervention Patients, n
Follow-up
Group difference
Zhang et al62
China, 2008–2011
1 surgeon
  1. Tourniquet for entire 
operation
2. Tourniquet removed 
before wound closure
3. Tourniquet from first 
bone osteotomy until 
closure
150 6 months
HSS score: no difference (p=0.839)
Transfusions: concern late 
tourniquet start in groups 1 and 2
Compression bandage
Brock et al70
UK, 2013–2014
1 hospital
Hydrocolloid dressing 1. Compression bandage
2. Standard crepe 
bandage
49 6 months
OKS: no difference (p=0.58)
Blood conservation
Hourlier et al67
France, 2009–2010
1 hospital
Drain, tourniquet, 
electrocautery
1. Continuous infusion 
tranexamic acid
2. Control saline
106 6 months
KSS: no difference (p=0.90)
Huang et al60
China, 2015
1 centre
Tourniquet 1. Intravenous and topical 
tranexamic acid
2. No tranexamic acid
100 6 months
VAS pain: no difference (p=0.728)
HSS score: strong evidence 
favouring tranexamic acid (p<0.001). 
Mean difference (1.4/100) lower than 
MCID (8.3/100)
Blood loss: control concern
Kim et al63
Korea, 2009–2011
1 hospital
Tourniquet, drain, 
compressive dressing
1. Tranexamic acid
2. No tranexamic acid
180 1 year
WOMAC pain: no significant 
difference
Transfusion: control concern
Kusuma et al68
USA, before 2013
1 hospital
Tourniquet, Esmarch 
bandage, electrocautery
1. Thrombin infusion
2. No thrombin infusion
80 6 months, 1 and 2 years
KSS: no difference (p=0.45)
Napier et al69
UK, 2003–2004
1 hospital
  1. Passive flexion
2. Passive extension
180 1 year
OKS: no difference (p=0.27)
Transfusion: extension concern
Sa-Ngasoongsong et al64
Thailand, 2008–2009
1 hospital
Drain and compressive 
dressing
1. Tranexamic acid
2. Control saline
48 6 months
WOMAC score: no difference 
(p=0.282)
Transfusion: control concern
Sa-Ngasoongsong et al65
Thailand, 2010–2011
1 hospital
Drain and compressive 
dressing
1. Tranexamic acid 
500 mg
2. Tranexamic acid 
250 mg
3. Control saline
135 1 year
WOMAC score: no difference 
(p=0.42)
Transfusions: control and 250 mg 
group concerns
Denosumab
Ledin et al72
Sweden, 2012–2014
2 centres
  1. Denosumab
2. Placebo
50 1 and 2 years
KOOS pain: no significant difference
Continuous passive motion
Bennett et al74
Australia, 1997–2000
1 hospital
Physiotherapy 1. Standard CPM
2. Early flexion CPM
3. No CPM
147 1 year
KSS: no significant difference
Ersözlü et al73
Turkey, 2003–2004
1 hospital
Physiotherapy 1. CPM low and 
increasing
2. CPM high and 
increasing
3. No CPM
90 2 years
KSS: no difference (p=0.67)
Electrical stimulation
Table 1 Continued
Continued
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Study, country, patient 
recruitment dates
Setting
Treatment common to 
randomised groups Intervention Patients, n
Follow-up
Group difference
Avramidis et al75
Greece, 2005–2006
1 hospital
Physiotherapy 1. Transcutaneous electric 
muscle stimulation
2. No treatment
76 1 year
SF-36 bodily pain: strong evidence 
favouring electrical stimulation 
(p<0.001). Mean difference 
(12.5/100) close to MCID (16.9/100).
OKS/ KSS: no difference
Moretti et al77
Italy, 2008–2010
1 hospital
Rehabilitation protocol 1. Pulsed electromagnetic 
fields
2. No treatment
30 6 months and 1 year
VAS pain: some evidence favouring 
electrical stimulation (p<0.05). Mean 
difference (2.1/10) greater than 
MCID (16.1/100)
Knee swelling: electrical stimulation 
concern
Rehabilitation
Li et al79
China, 2015–2016
1 hospital
Standard rehabilitation 1. Walking guidance and 
training
2. No treatment
86 6 months
VAS pain/ HSS score: some 
evidence favouring walking (both 
p<0.01). Mean VAS pain difference 
(2.4/100) greater than MCID 
(16.1/100)
Liebs et al81
Germany, 2003–2004
4 hospitals
CPM, physiotherapy, 
postdischarge aquatic 
therapy
1. Early aquatic therapy
2. Delayed aquatic 
therapy
185 6 months, 1 and 2 years
WOMAC pain: no difference (p=0.22 
at 12 months)
Mahomed et al82
Canada, 2000–2002
2 centres
Physiotherapy 1. Multidisciplinary 
supported early 
discharge and home 
physiotherapy
2. Transfer to 
rehabilitation centre
234 hip 
or knee 
replacement
1 year
WOMAC pain: weak evidence 
favouring supported discharge 
(p=0.08). Mean difference (4) less 
than MCID (8–9)
Wang et al80
China, 2009–2010
1 centre
  1. Wound closure in 
flexion
2. Wound closure in 
extension
80 6 months
VAS pain: no difference (p=0.64)
Wound management
Kong et al71
South Korea, 2011
1 surgeon
Skin staples and closure 
strip
1. Silicone gel
2. Petroleum gel
100 6 months and 1 year
VAS pain: no difference (6 months 
p=0.886, 1 year p=0.201)
Anabolic steroids
Hohmann et al83
Australia, Before 2010
1 surgeon
CPM. Cold compression 1. Intramuscular 
nandrolone injections
2. Saline injections
10 6 and 9 months, 1 year
KSS: some evidence favouring 
nandrolone (6 months p=0.04, 9 
months p=0.06, 12 months p=0.03). 
Difference at 12 months (10.2) close 
to MCID (12.3)
Bone mineral density: weak 
evidence favouring nandrolone
ACB, adductor canal block; CPM, continuous passive motion; DN4, Douleur Neuropathique 4; FNB, femoral nerve block; HSS, Hospital 
for Special Surgery; KOOS, Knee injury and Osteoarthritis Outcome Score; KSS, Knee Society Score; LIA, local infiltration analgesia; 
MCID, minimal clinically important difference; NRS, numerical rating scale; OKS, Oxford Knee Score; PCA, patient-controlled analgesia; 
SF-36, Short Form 36 Health Survey; S-LANSS, Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale; SNB, sciatic nerve 
block; VAS, visual analogue scale; VTE, venous thromboembolism; WOMAC, Western Ontario and McMaster Universities Osteoarthritis 
Index.
Table 1 Continued
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Similarly, there were no differences between single-shot 
SNB and PCA in WOMAC pain scale or VAS-rated pain at 
rest or during mobilisation, or between continuous SNB 
and PCA.
Local anaesthetic infiltration
In six RCTs, treatment with LIA was investigated.
Three RCTs compared intraoperative LIA with placebo 
or no intervention. In one study, all 280 participants 
received FNB and PCA.45 There was weak evidence that 
WOMAC pain scores were better in the LIA group at 6 
months (p=0.063) but not at 12 months (p=0.107) when 
the difference in means of 3.8/100 was lower than the 
MCID of 8–9/100 reported by Ehrich and colleagues.46 
In another study, 56 patients received LIA including 
ketorolac, or saline placebo, and all received PCA.47 At 
1 year, mean differences and CIs provided weak evidence 
that OKS scores were better in the LIA group but the 
difference in means of 2.7/48 was less than the MCID 
of 4/48 reported by Beard and colleagues.48 LIA before 
surgical incision was compared with placebo in one study 
with 120 participants.49 None received FNB or PCA. 
There was weak evidence for a better KSS (function and 
knee score components) at 6 months in those receiving 
LIA (p=0.07) with a difference in means of 14.2/200 
exceeding the MCID of 12.3/200 reported by Lee and 
colleagues.50
In one study, 51 participants received LIA intraopera-
tively, followed by PCA.51 Those randomised to further 
postoperative catheter-delivered LIA with ketorolac, or 
saline placebo had similar VAS-rated pain at 6 and 12 
months.
LIA delivered as an injection and postoperative infu-
sion was compared with epidural PCA in one study with 
222 patients.52 There was no difference between groups 
in OKS at 12 months.
In one study of 100 participants, LIA with or without 
corticosteroid were compared.53 All patients received 
PCA. At 2 years there was no difference in OKS between 
groups.
Oral celecoxib
In one RCT, 44 participants received oral celecoxib or 
placebo,54 as well as PCA. There were no differences 
between groups in KOOS or VAS-rated pain at 12 months.
Ketamine or nefopam infusion
In one RCT, ketamine infusion, nefopam infusion and 
saline placebo were compared in 75 patients, all of whom 
received PCA.55 VAS-rated pain on movement did not 
differ between groups at 12 months. For the Douleur 
Neuropathique 4 measure of neuropathic pain, there was 
some evidence favouring ketamine over placebo at 6 and 
12 months (p=0.02), but overall, few patients reported 
neuropathic pain at 12 months.
Pregabalin
Oral pregabalin was compared with placebo in one RCT 
with 240 participants.56 All received LIA and PCA. At 
6 months, there was some evidence for better NRS pain 
in patients receiving pregabalin compared with placebo 
(p=0.0176) but the difference in means of 0.54/10 
was less than the MCID of 1/10 reported by Salaffi 
and colleagues.57 No participants receiving pregabalin 
reported neuropathic pain when assessed using the 
S-LANSS, compared with 5.2% of those receiving placebo 
(p=0.014). Patients receiving pregabalin were more likely 
to be sedated and confused in the first 2 days after surgery.
tourniquet
Five studies with 399 participants explored tourniquet use 
to provide a bloodless field. Two studies each were from 
Australia and China, and one from Denmark. All were 
conducted at a single centre with participants recruited 
between 2008 and 2015. Sample sizes ranged from 20 to 
150 participants, with a median of 65. The range of mean 
ages of participants in randomised groups was 66–71 
years and in 3/5 studies, a majority of participants were 
women.
In three RCTs, participants received TKR with or without 
a tourniquet. In one study with 64 patients, a difference in 
KOOS pain favouring tourniquet use was not significant 
at 6 or 12 months.58 In another study with 20 patients, the 
OKS was not significantly different between groups at 6 or 
12 months.59 There were three blood transfusions in the 
tourniquet group, compared with none in the ‘no tour-
niquet’ group. In the third study with 100 participants, 
VAS-rated pain and HSS scores were similar between 
groups at 6 months.60 Six cases of wound ooze occurred 
in the tourniquet group.
In two RCTs, short and long-duration tourniquet use 
were compared. In one study with 65 participants, there 
was weak evidence based on graphical representation of 
means and CIs for improved OKS at 12 months in the 
long-duration group and the difference in means of 
5/4861 was greater than the MCID of 4/48. Adverse events 
were reported by 62% of participants receiving short-du-
ration tourniquet compared with 38% in the long-dura-
tion group. The study was terminated early as 10 blood 
transfusions were required in the short-duration group 
compared with three in the long-duration group. In the 
second study with 150 participants, tourniquets were used 
in three different periods during surgery.62 At 6 months, 
there were no differences between groups in HSS scores.
blood conservation
Seven studies with 829 participants evaluated strategies to 
limit blood loss after TKR. Two studies were from Thai-
land, and one each from China, France, South Korea, the 
UK and the USA. All were conducted at a single centre 
with participants recruited between 2003 and 2015 when 
stated. Sample sizes ranged from 48 to 180 participants, 
with a median of 106. One study had three trial arms. The 
range of mean ages of participants in randomised groups 
was 65–74 years and in all studies, a majority of partici-
pants were women.
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Tranexamic acid
Five RCTs evaluated tranexamic acid.
Tranexamic acid injections or infusions were compared 
with saline placebo or untreated control in four 
RCTs.60 63–65 In all studies, control patients required more 
blood transfusions. In one study including 180 participants 
comparing intravenous tranexamic acid with untreated 
controls, there was no significant difference in WOMAC 
pain scores at 1 year.63 In another study with 48 partici-
pants comparing intra-articular tranexamic acid injection 
with saline placebo, there was no significant difference 
in WOMAC scores at 6 months.64 One study with 135 
participants compared two intra-articular tranexamic 
acid doses and saline control.65 There were no significant 
differences in WOMAC scores at 1 year. Intravenous and 
intra-articular tranexamic was compared with untreated 
controls in one study with 100 participants.60 VAS-rated 
pain at 6 months was similar between groups, but there 
was strong evidence favouring tranexamic acid for HSS 
scores (p<0.001), although the difference in means of 
1.4/100 was lower than the MCID of 8.3/100 reported by 
Singh and colleagues.66
In one study, continuous tranexamic acid infusion was 
compared with a single bolus in 106 patients.67 There 
was no difference between groups in KSS at 6 months or 
blood loss.
Thrombin infusion
In one RCT with 80 participants, thrombin infusion was 
compared with untreated control.68 At 1 year there was no 
difference between groups in pain measured on the KSS.
Flexion or extension
For blood management, operated knees were kept in 
passive flexion or passive extension after surgery in 
one RCT with 180 patients.69 At 1 year, OKS was similar 
between groups. Transfusion requirement was greater in 
patients with passive extension.
Compression bandage
One RCT conducted at a single UK centre with 49 partic-
ipants recruited between 2013 and 2014 compared 
compression bandaging to reduce postoperative knee 
swelling with standard bandaging. The mean age of partic-
ipants was about 69 years and a majority were women. 
OKS was similar in randomised groups at 6 months.70
Wound management
One RCT with recruitment in 2011 at a single centre in 
South Korea evaluated a wound care strategy to limit 
postoperative scar pain. The mean age of participants was 
about 69 years and a majority were women. Investigators 
compared silicone gel application to the surgical scar 
with placebo in 100 participants.71 There were no signif-
icant differences in VAS-rated pain at 6 and 12 months.
denosumab
One RCT evaluated use of the antiresorptive monoclonal 
antibody denosumab to promote bone healing. The study 
was conducted in two centres in Sweden with recruitment 
of 50 participants between 2012 and 2014. The mean age 
of participants was about 65 years and a majority were 
women. At 12 and 24 months there were no significant 
differences between groups in KOOS pain.72
Continuous passive motion
Two RCTs with 237 participants evaluated use of CPM to 
minimise joint stiffness and improve range of movement. 
Studies were conducted in single centres in Australia and 
Turkey with participant recruitment between 1997 and 
2004 and both had three trial arms. Sample sizes were 
90 and 147 participants. The mean ages of participants 
in studies were about 63 and 72 years and a majority of 
participants were women. In one study, 90 participants 
were randomised to no CPM, CPM at low flexion from 
postoperative day 1 to day 7, or CPM at high flexion from 
postoperative day 3 to day 7.73 There was no significant 
difference between groups in KSS at 2 years. In the other 
study, 147 participants were randomised to CPM with 
increasing range of movement from day 1 to day 6, early 
flexion CPM from day 0 to day 6, or no CPM.74 There 
were no significant differences between groups in KSS at 
12 months.
electrical stimulation
Two RCTs with 106 participants conducted in single 
centres in Greece and Italy evaluated electrical stimula-
tion which is believed to have anti-inflammatory activity 
and limit muscle atrophy. Studies included 76 and 30 
participants recruited between 2005 and 2010. The mean 
ages of participants were 71 and 70 years and in one study 
that reported it, a majority of participants were female.
In one study with 76 participants receiving transcuta-
neous electric muscle stimulation from postoperative 
day 2 for 6 weeks or no intervention, SF-36 bodily pain 
showed strong evidence for greater improvement at 
1 year in the intervention group compared with control 
(p<0.001).75 The difference in means of 12.5/100 was 
close to the MCID of 16.9/100 reported by Escobar and 
colleagues.76 There were no differences in OKS or KSS 
scores. In another study with 30 participants, pulsed 
electromagnetic fields from postoperative day 7 were 
compared with untreated control.77 At 12 months, there 
was some evidence that VAS-rated pain was lower in inter-
vention patients compared with controls (p<0.05). The 
difference in means of 2.1/10 was greater than the MCID 
of 16.1/100 reported by Danoff and colleagues.78 Knee 
swelling was common during the intervention.
rehabilitation
Four RCTs with 585 participants recruited between 
2000 and 2016 evaluated features of early rehabilitation 
focusing on regaining range of movement, functional 
independence and improving mobility. Two studies were 
conducted at single centres in China and at two and four 
centres in Canada and Germany, respectively. Sample sizes 
ranged from 80 to 234 participants, with a median of 136. 
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The range of mean ages of participants in randomised 
groups was 68–78 years and in 3/4 studies, a majority of 
participants were women.
Walking guidance and training
In one study, 86 participants were randomised to walking 
guidance and training from postoperative day 2 or no 
intervention further to standard rehabilitation.79 At 
6 months, there was some evidence that those receiving 
intervention had lower VAS-rated pain (p<0.01) and HSS 
score (p<0.01) than controls. The difference in mean 
VAS-rated pain of 2.4/10 was greater than the MCID of 
16.1/100.
Flexion or extension during knee closure
Targeting improved functional recovery, wound closure 
performed in 90° flexion was compared with wound 
closure in full extension in one study with 80 partic-
ipants.80 There was no difference between groups in 
VAS-rated pain at 6 months.
Aquatic therapy
In one study with 185 participants, aquatic therapy 
commencing on postoperative day 6 was compared 
with aquatic therapy commencing on day 14.81 Patients 
reported similar WOMAC pain at 12 and 24 months.
Supported early discharge
In one study, early discharge supported by physiotherapist 
home visits and outpatient or self-directed physiotherapy 
was compared with 2 weeks of rehabilitation centre-based 
usual care.82 The study included 234 individuals receiving 
TKR or total hip replacement. Compared with usual 
care, there was weak evidence that patients with early 
discharge had lower WOMAC pain scores at 12 months 
(p=0.08). The difference in means of 4 was less than the 
MCID of 8–9/100. Results were not presented separately 
but did not differ between patients with TKR or total hip 
replacement.
Anabolic steroids
Searches identified one study of anabolic steroids to 
improve postoperative muscle strength conducted in one 
centre in Australia with recruitment of 10 participants 
before 2010. The mean age of participants was about 66 
years and a minority were women. Participants received 
intramuscular nandrolone injections or saline from post-
operative day 5 for 6 months. KSS results indicated some 
evidence for improvement in the intervention group 
compared with controls at 12 months (p=0.03).83 The 
difference in means of 10.2/200 was close to the MCID 
of 12.3/200.
dISCuSSIOn
Much research in TKR aims to identify treatments 
that facilitate a speedy recovery with minimal short-
term pain. However, patients choose to have joint 
replacement for long-term pain relief and reduction in 
functional limitations. Thus, changes to perioperative 
care, supported by short-term RCT evidence, should be 
backed up with evidence about long-term effectiveness 
for reducing pain and reassurance that there are no 
long-term unfavourable consequences. To this end, we 
synthesised evidence from RCTs evaluating periopera-
tive interventions which have considered their long-term 
effects on pain outcomes.
Consistent with its status as a key perioperative risk 
factor, a major focus of research into improving long-
term pain after TKR has been through prevention of 
acute postoperative pain using multimodal analgesia. Our 
review provides good-quality evidence for a small benefit 
for intra-articular LIA injections, as previously shown in 
short-term studies,31 84 oral pregabalin, oral opioids, and 
in relation to neuropathic pain, ketamine infusion. As 
well as potential benefits for reduced long-term pain, 
future studies will need to consider concerns associated 
with these interventions which may not have been identi-
fied in small studies including infection,31 venous throm-
boembolism36 and sedation.56
Nerve blocks are effective for managing perioperative 
pain85 but we identified no long-term benefit. In single 
studies, there was no benefit for nefopam infusion, 
oral celecoxib or LIA with additional corticosteroid. 
Regarding future studies, standardisation of the multi-
modal regimen will allow evaluation of extra or alterna-
tive components in multiple studies in different settings. 
With such an approach, convincing evidence will accrue 
to guide multimodal pain management.
Some interventions targeted the prevention of adverse 
events and facilitation of early mobilisation. Tranexamic 
acid is highly effective in reducing blood transfusions 
during TKR86 and we found no evidence that tranexamic 
acid affects long-term pain or, consistent with registry 
studies,87 88 adverse events. Single RCTs of thrombin infu-
sion and maintenance of knee in flexion to prevent blood 
loss showed no effect on long-term pain. Tourniquets 
improve intraoperative visualisation of the joint, reduce 
blood loss and facilitate cement fixation but are associ-
ated with nerve damage, delayed recovery, acute pain and 
need for analgesics.89 90 The RCTs we identified showed 
no effects of tourniquet use on long-term pain.
As shown in a previous review,91 there was no suggestion 
that CPM affects long-term pain. There was good-quality 
evidence for a small benefit for reduced long-term pain 
in patients receiving walking training, anabolic steroid 
injection, electrical stimulation and supported discharge.
For some interventions a direct mechanism is clear, 
but for others, reasons for long-term impact are less 
obvious. This may explain why, for example, no studies 
evaluated DVT prophylaxis with long-term follow-up 
excepting a small number reporting adverse events. 
However, treatments to prevent symptomatic DVTs which 
occur in about 1% of treated patients92 also reduce the 
incidence of asymptomatic DVT observed in about 28% 
of treated patients93 and this may have long-term bene-
fits. Conversely, new anticoagulants are associated with 
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bleeding,94 which may increase the risk of wound compli-
cations95 and joint infection96 which are associated with 
long-term pain.97 98 More perioperative interventions with 
no information on long-term pain outcomes from RCTs 
are shown in figure 1.
Our study is limited by the lack of meta-analysis which 
was not appropriate due to intervention and outcome 
heterogeneity. In the context of perioperative pain 
management, this was noted previously.84 Our approach 
to assessing the evidence was a narrative synthesis of 
studies with low risk of bias. While this may seem overly 
restrictive, Cochrane risk of bias assessment allows us to 
screen out studies with important issues that may affect 
the validity of results. The main potential source of bias 
was incomplete outcome assessment. Although studies 
with long-term follow-up are naturally at higher risk of 
missing data, we maintained a standard in this domain 
as it is recognised that research participants who do 
not complete follow-up assessments differ in outcomes 
from those with follow-up data and their inclusion could 
change the interpretation of results.99
Another limitation is that pain assessed with question-
naires does not take into account the effect of pain medi-
cations and assistive aids. About 58% of women and 40% 
of men report taking pain medications after TKR because 
of pain in the operated knee100 and we must recognise 
that pain levels at follow-up without this treatment might 
be considerably higher. Even with treatment, around 20% 
of patients report chronic pain after TKR10 and in the 
context of a blinded RCT we should expect to be able to 
identify effects of perioperative treatments.
We summarised p values to assess the strength of 
evidence but, as statistically strong evidence may not 
reflect clinically important results,101 where possible we 
also compared effect sizes with MCIDs. Our review consid-
ered a diverse range of interventions at a specific time in 
the TKR pathway and, as we were unable to make clinical 
practice recommendations, we did not adopt the Grades 
of Recommendation, Assessment, Development and Eval-
uation system102 for this review.
An alternative approach to the prevention of chronic 
pain after TKR is the individualisation of care based 
on pain phenotype, genetic, psychosocial and other 
factors.103 An example of this might be the perioperative 
treatment only of individuals with neuropathic pain with 
pregabalin, as opposed to the non-stratified provision in 
the RCT of Buvanendran and colleagues.56 In an RCT 
with pregabalin provided to patients with painful HIV 
neuropathy, while no overall benefit was seen, a group 
with hyperalgesia responded to pregabalin treatment.104
Our systematic review of perioperative interventions 
brings together evidence on interventions in the periop-
erative phase of the TKR pathway. There was good-quality 
evidence for some interventions of a small benefit for 
reduced long-term pain, and while not supportive of the 
inclusion of specific interventions in clinical practice, 
there are clearly areas that merit research. High-quality 
studies assessing long-term pain after perioperative 
interventions are feasible and necessary to ensure that 
patients with osteoarthritis achieve good long-term 
outcomes after TKR.
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